Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
ARAY 
Accuray Incorporated (ARAY)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
05/27/2025: ARAY (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
4 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $5.17
1 Year Target Price $5.17
| 3 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -65.75% | Avg. Invested days 27 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 05/27/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 141.13M USD | Price to earnings Ratio - | 1Y Target Price 5.17 |
Price to earnings Ratio - | 1Y Target Price 5.17 | ||
Volume (30-day avg) 4 | Beta 1.31 | 52 Weeks Range 1.14 - 2.95 | Updated Date 06/30/2025 |
52 Weeks Range 1.14 - 2.95 | Updated Date 06/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 0.15% | Operating Margin (TTM) 3.73% |
Management Effectiveness
Return on Assets (TTM) 1.72% | Return on Equity (TTM) 1.49% |
Valuation
Trailing PE - | Forward PE 94.34 | Enterprise Value 277157269 | Price to Sales(TTM) 0.3 |
Enterprise Value 277157269 | Price to Sales(TTM) 0.3 | ||
Enterprise Value to Revenue 0.6 | Enterprise Value to EBITDA 13.45 | Shares Outstanding 103013000 | Shares Floating 99601581 |
Shares Outstanding 103013000 | Shares Floating 99601581 | ||
Percent Insiders 2.27 | Percent Institutions 62.55 |
Analyst Ratings
Rating 2 | Target Price 5.17 | Buy 1 | Strong Buy 3 |
Buy 1 | Strong Buy 3 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Accuray Incorporated
Company Overview
History and Background
Accuray Incorporated was founded in 1990. It pioneered stereotactic radiosurgery and radiation therapy with the CyberKnife and TomoTherapy platforms, focusing on precision and minimally invasive cancer treatment.
Core Business Areas
- Radiation Oncology Systems: Designs, develops, and markets radiation therapy and radiosurgery systems, including the CyberKnife and TomoTherapy platforms.
- Service: Provides service and support for its installed base of radiation therapy systems, including maintenance, training, and upgrades.
Leadership and Structure
Suzanne Winter is the President and CEO. The company operates with a functional organizational structure focused on research and development, sales and marketing, manufacturing, and service.
Top Products and Market Share
Key Offerings
- Competitors: Varian Medical Systems (Siemens Healthineers), Elekta
- CyberKnife Robotic Radiosurgery System: A robotic radiosurgery system that delivers precise radiation to tumors throughout the body. It competes with Varian Medical Systems' Edge and Elekta's Gamma Knife. Market share information is not readily available publicly.
- Competitors: Varian Medical Systems (Siemens Healthineers), Elekta
- TomoTherapy System: A radiation therapy system that uses a CT scanner-like design to deliver intensity-modulated radiation therapy (IMRT). It competes with Varian Medical Systems' TrueBeam and Elekta's Versa HD. Market share information is not readily available publicly.
Market Dynamics
Industry Overview
The radiation oncology market is growing due to an aging population and increasing cancer incidence. Key trends include precision radiation therapy, minimally invasive techniques, and advanced imaging integration.
Positioning
Accuray is positioned as a technology innovator in precision radiation therapy, particularly with its CyberKnife system. Its competitive advantage lies in its robotic accuracy and minimally invasive approach.
Total Addressable Market (TAM)
The global radiotherapy market is projected to reach over $8 billion by 2028. Accuray is positioned to capture a portion of this market through its innovative solutions.
Upturn SWOT Analysis
Strengths
- Innovative CyberKnife technology
- Strong service revenue stream
- Focus on precision and minimally invasive treatments
Weaknesses
- Smaller market share compared to Varian and Elekta
- High system costs
- Dependence on capital equipment sales
Opportunities
- Expanding into emerging markets
- Developing new applications for CyberKnife and TomoTherapy
- Collaborating with other healthcare providers
Threats
- Intense competition from Varian and Elekta
- Technological advancements by competitors
- Healthcare cost containment pressures
Competitors and Market Share
Key Competitors
- VAR
- ELEK
Competitive Landscape
Accuray offers unique robotic radiosurgery capabilities with the CyberKnife, but it faces stiff competition from Varian and Elekta, which have larger market shares and broader product portfolios. Accuray's advantage is its specialization, while its disadvantage is its smaller scale.
Growth Trajectory and Initiatives
Historical Growth: Historical growth trends require analysis of past financial statements.
Future Projections: Future growth projections require analyst estimates.
Recent Initiatives: Recent initiatives include expanding its product portfolio with new software upgrades and focusing on global expansion.
Summary
Accuray is an innovative company in the radiation oncology space, particularly known for its CyberKnife robotic radiosurgery system. While its technology is a strength, it faces significant competition from larger players like Varian and Elekta. Focus on market share growth and strategic partnerships is critical for Accuray's success. The financial performance remains a point of concern and requires further improvement.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Accuray Incorporated Investor Relations
- Industry Reports
- Market Research Reports
- SEC Filings
Disclaimers:
This analysis is based on publicly available information and is for informational purposes only. It should not be considered financial advice. Market share data are estimates based on available information and may not be precise. Financial data and analyst estimates were not provided due to data retrieval constraints.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Accuray Incorporated
Exchange NASDAQ | Headquaters Madison, WI, United States | ||
IPO Launch date 2007-02-08 | President, CEO & Director Ms. Suzanne Winter M.B.A. | ||
Sector Healthcare | Industry Medical Devices | Full time employees 987 | Website https://www.accuray.com |
Full time employees 987 | Website https://www.accuray.com | ||
Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Asia, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China. It offers the CyberKnife platform, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate. The company also provides the TomoTherapy platform, including the Radixact System, which allows for integrated radiation treatment planning, delivery, and data management, enabling clinicians to deliver ultra-precise treatments to approximately 50 patients per day; iDMS data management system, a fully integrated treatment planning and data management systems; and Accuray precision treatment planning system, a treatment planning and data management systems. In addition, it offers post-contract customer support, installation, training, and other professional services. The company primarily markets its products directly to customers, including hospitals and stand-alone treatment facilities through its sales organization, as well as to customers through sales agents and group purchasing organizations in the United States; and to customers directly and through distributors and sales agents internationally. Accuray Incorporated was incorporated in 1990 and is headquartered in Madison, Wisconsin.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.